PDCD1 and metastatic melanoma: In an attempt to identify early and reliable biomarkers of survival prediction in immunotherapy of metastatic melanoma, we assessed the prognostic role of interim [18F]FDG PET/CT performed after the first two cycles of anti-PD-1 treatment.